Compare VSEC & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VSEC | TGTX |
|---|---|---|
| Founded | 1959 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 5.0B |
| IPO Year | 1995 | 2008 |
| Metric | VSEC | TGTX |
|---|---|---|
| Price | $222.71 | $30.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 6 |
| Target Price | ★ $221.71 | $50.67 |
| AVG Volume (30 Days) | 705.6K | ★ 1.3M |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 0.18% | N/A |
| EPS Growth | N/A | ★ 66.67 |
| EPS | N/A | ★ 2.62 |
| Revenue | ★ $760,113,000.00 | $2,785,000.00 |
| Revenue This Year | $3.78 | $90.97 |
| Revenue Next Year | $21.59 | $45.74 |
| P/E Ratio | ★ N/A | $11.27 |
| Revenue Growth | ★ 9.88 | N/A |
| 52 Week Low | $98.27 | $25.37 |
| 52 Week High | $229.02 | $46.48 |
| Indicator | VSEC | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 56.73 |
| Support Level | $158.16 | $29.81 |
| Resistance Level | $225.00 | $33.05 |
| Average True Range (ATR) | 10.15 | 1.08 |
| MACD | 1.75 | 0.16 |
| Stochastic Oscillator | 84.50 | 85.66 |
VSE Corp is a diversified aftermarket products and services company providing repair services, parts distribution, logistics, supply chain management, and consulting services for land, sea, and air transportation assets to commercial and government markets. Its operations include supply chain management solutions, parts supply and distribution, and maintenance, repair, and overhaul (MRO) services for vehicle fleet, aviation, maritime and other customers. Its reportable segments are; Aviation and Fleet. The majority of the revenue for the company is generated from the Aviation segment which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.